Soft Bank Ventures has disclosed, together with Interbest, Megainvestment, that they have invested 3 billion won in Speclipse. Speclipse has developed early skin cancer diagnosis technology that doesn’t damage skin.
By analyzing skin and checking the spectrum with laser beam splitting technology, startup Speclipse has developed early skin cancer diagnosis technology that doesn’t damage skin.
Speclipse received 3 billion won of investment from Soft Bank Ventures, Interbest, and Megainvestment
A Speclipse representative told us, “It’s hard to tell between skin cancer tissue and benign spots. Before skin cancer symptoms appear or you have a health examination, it’s currently impossible to diagnose it at the early stages. There are no errors when comparing Speclipse’s technology with health examination results. Speclipse’s technology allows patients to treat themselves at an early stage. It will definitely make a great contribution to the medical industry.”
Soft Bank Ventures investment reviewer Chang Yujin said, “Speclipse diagnoses skin cancer accurately according to chemical component analysis and prevents patients from damaging their skin. We look forward to its development in the international medical market.”
Speclipse representative Byoun Seonghyeon said, “Speclipse’s laser technology brings new opportunities to skin cancer diagnosis. We hope it becomes a pioneer in the global life science industry. Through this investment, Speclipse will quickly gain overseas certification and marketing, and build up a foundation for its development.”
